Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma

Abstract. Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to daratumumab monotherapy and collecte...

Full description

Bibliographic Details
Main Authors: Adrián Alegre, Javier de la Rubia, Anna Sureda Balari, Cristina Encinas Rodríguez, Alexia Suárez, María Jesús Blanchard, Joan Bargay Lleonart, Paula Rodríguez-Otero, Andrés Insunza, Luis Palomera, María Jesús Peñarrubia, Rafael Ríos-Tamayo, Luis Felipe Casado Montero, Marta Sonia González, Anna Potamianou, Catherine Couturier, Huiling Pei, Henar Hevia, Iordanis Milionis, Maren Gaudig, María-Victoria Mateos
Format: Article
Language:English
Published: Wolters Kluwer 2020-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000380

Internet

http://journals.lww.com/10.1097/HS9.0000000000000380

Similar Items